pSivida: Out-licensing of BioSiliconTM to PureTech Development LLC
Global nanotechnology company pSivida Limited announced that it has signed an agreement with US based PureTech Development LLC ("Puretech") to investigate and evaluate out-licensing opportunities for BioSiliconTM with an emphasis on tissue engineering, wound management and orthopedics.
Through a range of collaborative partnerships and internal R&D over the last four years, pSivida has developed the BioSiliconTM (nano-structured porous elemental silicon) technology platform in non-core areas such as tissue engineering, wound management and orthopedics to a point where it is in a position and in line with the Company's broader commercialization strategy, to seek suitable partners in these specialist areas of healthcare.
pSivida has commissioned PureTech to explore with suitable partners, arrangements for evaluating the potential of BioSiliconTM in their areas of expertise and such partnerships would be expected to produce, in due course, revenue in the form of upfront and milestone payments as BioSiliconTM based products are developed and commercialized.
Most read news
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Pestalotiopsis_leprogena
Cosmo holds 94.7% of BioXell voting rights and shares
International_Ragdoll_Cat_Association
Estonian Biotechnolgy Association - Tallinn, Estonia
Category:Podiatrists
Clinuvel's afamelanotide to commence US patient trials for absolute light intolerance
Black_Death
Tyrosine_sulfation
Cytheris announces results of phase IIa study indicating that recombinant interleukin-7 (CYT107) expands CD4 T-Cells in gut mucosa of chronically HIV infected immunological non-responder patients
